How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated. The extent to which cancer rates in RA vary across clinical cohorts and patient subsets, as defined by disease activity or treatment is less known but critical for understanding the safety of existing and new antirheumatic therapies. We investigated comparability of, and means to harmonise, malignancy rates in five RA registries from four continents.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann. Rheum. Dis.

Title: Annals of the rheumatic diseases

Publisher: BMJ

ISSN (Electronic): 1468-2060

ISSN (Print): 0003-4967

Publication date (Electronic): Oct 2016

Volume: 75

Issue: 10

Affiliations

[1 ] Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden.

[2 ] Biometric & Information Sciences, Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden.

[3 ] Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

[4 ] Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK.

[5 ] NYU School of Medicine, New York, New York, USA Corrona LLC, Southborough, Massachusetts, USA.

[6 ] Clinical, Global Medicines Development, AstraZeneca R&D, Macclesfield, UK.

[7 ] Medical Evidence & Observational Research Centre, Global Medicines Development, AstraZeneca R&D, Wilmington, Delaware, USA.

[8 ] Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan.

[9 ] National Data Bank for Rheumatic Diseases, Wichita, Kansas, USA Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

[10 ] Medical Evidence & Observational Research Centre, Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

[11 ] Columbia University College of Physicians and Surgeons, New York, New York, USA.

[12 ] University of Massachusetts Medical School, Worcester, Massachusetts, USA.

[13 ] MedImmune, Gaithersburg, Maryland, USA.

[14 ] Patient Safety, GRAPSQA, Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden.

[15 ] Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Article

Publisher Item ID: annrheumdis-2015-208105

DOI: 10.1136/annrheumdis-2015-208105

PubMed ID: 26621482

SO-VID: 197f1bed-45df-43fa-9a4d-57f175496db3

History

Keywords: Epidemiology,Rheumatoid Arthritis,Outcomes research

Data availability:

Keywords: Epidemiology, Rheumatoid Arthritis, Outcomes research

Comments

Comment on this article

scite_

Cited by 14

See all cited by